NASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $28.65 -0.91 (-3.08%) Closing price 04:00 PM EasternExtended Trading$28.64 -0.01 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunocore Stock (NASDAQ:IMCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunocore alerts:Sign Up Key Stats Today's Range$27.97▼$29.7950-Day Range$27.91▼$31.9652-Week Range$27.56▼$40.71Volume648,635 shsAverage Volume358,031 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$56.71Consensus RatingModerate Buy Company Overview Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need. The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma. Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.AI Generated. May Contain Errors. Read More Immunocore Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreIMCR MarketRank™: Immunocore scored higher than 55% of companies evaluated by MarketBeat, and ranked 492nd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 4 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialImmunocore has a consensus price target of $56.71, representing about 98.0% upside from its current price of $28.65.Amount of Analyst CoverageImmunocore has only been the subject of 4 research reports in the past 90 days.Read more about Immunocore's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth1,350.00% Earnings GrowthEarnings for Immunocore are expected to grow by 1,350.00% in the coming year, from $0.06 to $0.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -52.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -52.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.68% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 0.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.63 News SentimentImmunocore has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunocore this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMCR Stock News HeadlinesAssessing Immunocore Holdings (IMCR) Valuation After New Brenetafusp Data At The 2026 ASCO MeetingJune 1 at 5:22 PM | finance.yahoo.comImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaMay 31 at 8:00 AM | globenewswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 3 at 1:00 AM | Weiss Ratings (Ad)Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 ShMay 14, 2026 | cnn.comA Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival DataMay 8, 2026 | finance.yahoo.comImmunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And EfficiencyMay 7, 2026 | finance.yahoo.comImmunocore reports first quarter financial results and provides a business updateMay 6, 2026 | globenewswire.comKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaApril 19, 2026 | globenewswire.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $34.71 at the beginning of the year. Since then, IMCR stock has decreased by 17.5% and is now trading at $28.65. How were Immunocore's earnings last quarter? Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) announced its quarterly earnings data on Wednesday, May, 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.51. Immunocore's revenue for the quarter was up 13.6% on a year-over-year basis. When did Immunocore IPO? Immunocore (IMCR) raised $238 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 9,935,896 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional investors include Janus Henderson Group PLC (1.17%), Principal Financial Group Inc. (1.02%), Bank of America Corp DE (0.41%) and Renaissance Technologies LLC (0.32%). Insiders that own company stock include Bros Advisors Lp Baker, Bahija Jallal, David M Berman, Leger Tina Amber St and John Goll. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunocore own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/06/2026Today6/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IMCR's financial health is in the Yellow zone, according to TradeSmith. IMCR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year Founded2008Price Target and Rating Average Price Target for Immunocore$56.71 High Price Target$100.00 Low Price Target$33.00 Potential Upside/Downside+98.0%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E Ratio477.50 P/E GrowthN/ANet Income-$35.51 million Net Margins-6.68% Pretax Margin-2.89% Return on Equity-7.07% Return on Assets-2.55% Debt Debt-to-Equity Ratio1.00 Current Ratio4.18 Quick Ratio4.15 Sales & Book Value Annual Sales$400.02 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book3.81Miscellaneous Outstanding Shares50,690,000Free Float45,575,000Market Cap$1.45 billion OptionableOptionable Beta0.74 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:IMCR) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
